| United States | 2,000 mgreference, not a law · 20%Comparison note2,500 mg (ages 19–50) · 2,000 mg (51 and older) | 3,000 mgreference, not a law · 6%Comparison note4,000 mg (ages 19–70) · 3,000 mg (71 and older) | 350 mgreference, not a law · 19% | —not on file |
| Austria | 800 mgrecommendation · 51% | 800 mgrecommendation · 24% | 375 mgrecommendation · 18% | 500 mgrecommendation · 90% |
| Belgium | 1,600 mglaw · 25% | —not on file | 450 mglaw · 15% | 6,000 mglaw · 8% |
| Croatia | 1,500 mglaw · 27% | 1,400 mglaw · 14% | 375 mglaw · 18% | 2,000 mglaw · 23% |
| Cyprus | 1,500 mglaw · 27% | 1,100 mglaw · 17% | 300 mglaw · 22% | —not on file |
| Denmark | 1,327 mgrecommendation · 31% | —not on file | 233 mgrecommendation · 28% | 3,000 mgrecommendation · 15% |
| EAEU | 2,500 mglaw · 16% | 1,600 mglaw · 12% | 800 mglaw · 8% | 3,500 mglaw · 13% |
| Estonia | 2,500 mgrecommendation · 16% | 3,000 mgrecommendation · 6% | 250 mgrecommendation · 26% | —not on file |
| Finland | 2,500 mgrecommendation · 16% | —not on file | 250 mgrecommendation · 26% | —not on file |
| France | 800 mglaw · 51% | 450 mglaw · 42% | 300 mglaw · 22% | 80 mglaw · 563% · above |
| Germany | 500 mgrecommendation · 81% | 0 mgrecommendation · not compared · above | 250 mgrecommendation · 26% | 500 mgrecommendation · 90% |
| Ireland | 2,500 mgrecommendation · 16% | —not on file | 250 mgrecommendation · 26% | —not on file |
| Italy | 1,200 mgrecommendation · 34% | —not on file | 450 mgrecommendation · 15% | —not on file |
| Luxembourg | 1,600 mglaw · 25% | 1,400 mglaw · 14% | 562.5 mglaw · 12% | 3,360 mglaw · 13% |
| Malta | 1,500 mgrecommendation · 27% | 250 mgrecommendation · 76% | 400 mgrecommendation · 17% | 3,700 mgrecommendation · 12% |
| Norway | 705 mglaw · 57% | —not on file | 350 mglaw · 19% | —not on file |
| Poland | 1,500 mgrecommendation · 27% | 450 mgrecommendation · 42% | 400 mgrecommendation · 17% | 1,500 mgrecommendation · 30% |
| Switzerland | 750 mglaw · 54% | —not on file | 375 mglaw · 18% | 2,250 mglaw · 20% |